Baseimmune

Mutation-proof vaccines that are prepared for future virus variants.

Summary

University:

Stage:

Seed

Sector:

Life Science

Investment year:

2021

Baseimmune focuses on the antigen, which is the part of a vaccine that mimics the virus. Their platform tells vaccine developers which parts of a virus should be put into the antigen to maximise immune response. Critically, the Baseimmune platform can predict how variants of a virus will evolve. This allows Baseimmune to develop vaccines that are prepared for future mutations.

The Baseimmune team comes from the renowned Jenner Institute for vaccine research at Oxford. The CEO Josh and CSO Ariane both have PhDs and postdocs in vaccines, and the third co-founder Phil is a self-taught computer scientist who did not attend university.

“A virus is a moving dart board; you need an antigen that is prepared for how it will move, if you want to keep hitting the bullseye.”

Joshua Blight